The National Institutes of Health Anticonvulsant Drug Development Program: screening for efficacy

Area of Science:

• Pharmacology and Toxicology
• Neuroscience and Neurology
• Drug Discovery and Development

Background:

• Epilepsy affects millions globally, with many patients experiencing uncontrolled seizures or adverse drug effects from current treatments.
• Developing safer and more effective anticonvulsant drugs with novel mechanisms of action is a critical unmet medical need.
• Predicting long-term drug safety, including tolerance and drug-drug interactions, is essential before clinical use.

Purpose of the Study:

• To outline a comprehensive testing protocol for evaluating new anticonvulsant drug candidates.
• To assess the anticonvulsant profile, tolerance, and potential for drug-drug interactions of novel substances.
• To gain preliminary insights into the mechanism of action for promising anticonvulsant compounds.

Main Methods:

• Utilizing the Anticonvulsant Screening Program (ASP) procedures to determine anticonvulsant activity.
• Conducting tolerance studies to assess the development of resistance to drug effects over time.
• Performing liver microsomal studies to predict potential drug-drug interactions.
• Employing in vitro mechanism-of-action studies to elucidate the molecular targets of candidate drugs.

Main Results:

• The ASP provides detailed anticonvulsant profiles for new candidate substances.
• Tolerance and liver microsomal studies offer critical data for predicting long-term safety and drug interaction risks.
• In vitro studies yield preliminary information on the sites of action for promising anticonvulsants.

Conclusions:

• The described testing protocol is anticipated to identify safer anticonvulsant substances with novel mechanisms.
• This approach aims to significantly improve the quality of life for epilepsy patients with uncontrolled seizures or adverse drug effects.
• The protocol facilitates the discovery of next-generation antiepileptic drugs.